Medigen Biotechnology Corporation(TW:3176)
30.10-3.15 (-9.47%)
TW:3176
Medigen Biotechnology Corporation financials statements
30.10
At close:-3.15 (-9.47%)
Medigen Biotechnology Corporation (3176) Ratios
Medigen Biotechnology Corporation Ratios
TW:3176's free cash flow for Q2 2026 was NT$-126.05M. For the 2026 fiscal year, TW:3176's free cash flow was decreased by NT$-46.66M and operating cash flow was NT$-79.39M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.68 | 3.96 | 2.05 | 6.40 | 4.62 |
| Quick Ratio | 3.90 | 3.26 | 1.86 | 5.74 | 3.91 |
| Cash Ratio | 1.78 | 1.50 | 0.80 | 1.94 | 2.01 |
| Solvency Ratio | 0.05 | -0.02 | -0.11 | -0.14 | 0.08 |
| Operating Cash Flow Ratio | 0.07 | 0.04 | -0.18 | -1.07 | 0.49 |
| Short-Term Operating Cash Flow Coverage | 0.20 | 0.12 | -0.23 | -3.16 | 1.41 |
| Net Current Asset Value | NT$ 2.02B | NT$ 1.99B | NT$ 2.18B | NT$ 3.22B | NT$ 3.14B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.15 | 0.16 | 0.34 | 0.28 | 0.13 |
| Debt-to-Equity Ratio | 0.61 | 0.68 | 1.83 | 1.28 | 0.43 |
| Debt-to-Capital Ratio | 0.38 | 0.40 | 0.65 | 0.56 | 0.30 |
| Long-Term Debt-to-Capital Ratio | 0.21 | 0.21 | 0.22 | 0.49 | 0.16 |
| Financial Leverage Ratio | 3.99 | 4.24 | 5.36 | 4.55 | 3.42 |
| Debt Service Coverage Ratio | -0.22 | -0.03 | -0.55 | -4.29 | 3.35 |
| Interest Coverage Ratio | -6.79 | -5.79 | -22.08 | -42.25 | 41.39 |
| Debt to Market Cap | 0.15 | 0.16 | 0.43 | 0.53 | 0.10 |
| Interest Debt Per Share | 7.00 | 7.93 | 21.30 | 20.48 | 7.60 |
| Net Debt to EBITDA | -19.89 | -3.23 | -0.66 | -0.47 | -0.82 |
| Profitability Margins | |||||
| Gross Profit Margin | 54.20% | 54.91% | 53.32% | 6.92% | 64.59% |
| EBIT Margin | -9.92% | -5.56% | -105.64% | -173.60% | 29.45% |
| EBITDA Margin | 1.18% | 7.21% | -90.23% | -155.45% | 34.51% |
| Operating Profit Margin | -9.92% | -15.35% | -106.51% | -157.87% | 20.12% |
| Pretax Profit Margin | -13.81% | -8.21% | -110.46% | -152.51% | 31.48% |
| Net Profit Margin | -6.88% | -14.91% | -48.48% | -64.01% | -1.34% |
| Continuous Operations Profit Margin | -18.70% | -16.20% | -126.98% | -182.92% | 27.29% |
| Net Income Per EBT | 49.77% | 181.60% | 43.89% | 41.97% | -4.26% |
| EBT Per EBIT | 139.24% | 53.49% | 103.71% | 96.61% | 156.52% |
| Return on Assets (ROA) | -1.76% | -3.05% | -6.58% | -6.77% | -0.64% |
| Return on Equity (ROE) | -7.02% | -12.94% | -35.27% | -30.81% | -2.20% |
| Return on Capital Employed (ROCE) | -2.89% | -3.64% | -21.45% | -18.67% | 11.06% |
| Return on Invested Capital (ROIC) | -2.76% | -3.43% | -15.53% | -17.92% | 9.96% |
| Return on Tangible Assets | -1.79% | -3.10% | -6.67% | -6.85% | -0.65% |
| Earnings Yield | -2.41% | -4.54% | -9.20% | -14.46% | -0.66% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.56 | 4.57 | 3.52 | 2.28 | 4.90 |
| Payables Turnover | 12.71 | 8.22 | 7.12 | 6.54 | 11.63 |
| Inventory Turnover | 1.25 | 0.96 | 0.99 | 1.42 | 1.85 |
| Fixed Asset Turnover | 0.85 | 0.69 | 0.57 | 0.48 | 1.79 |
| Asset Turnover | 0.26 | 0.20 | 0.14 | 0.11 | 0.48 |
| Working Capital Turnover Ratio | 0.58 | 0.48 | 0.27 | 0.22 | 1.32 |
| Cash Conversion Cycle | 344.08 | 415.90 | 421.85 | 361.77 | 240.88 |
| Days of Sales Outstanding | 80.08 | 79.88 | 103.69 | 160.35 | 74.45 |
| Days of Inventory Outstanding | 292.73 | 380.40 | 369.40 | 257.21 | 197.82 |
| Days of Payables Outstanding | 28.73 | 44.38 | 51.24 | 55.79 | 31.38 |
| Operating Cycle | 372.80 | 460.28 | 473.09 | 417.56 | 272.27 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.35 | 0.27 | -3.61 | -8.11 | 3.72 |
| Free Cash Flow Per Share | -0.16 | -0.15 | -3.91 | -9.19 | 2.68 |
| Dividend Paid and CapEx Coverage Ratio | 0.69 | 0.34 | -13.11 | -6.22 | 3.58 |
| Capital Expenditure Coverage Ratio | 0.69 | 0.65 | -13.11 | -7.45 | 3.58 |
| Operating Cash Flow Coverage Ratio | 0.05 | 0.04 | -0.17 | -0.40 | 0.50 |
| Operating Cash Flow to Sales Ratio | 0.03 | 0.03 | -0.43 | -1.07 | 0.13 |
| Free Cash Flow Yield | -0.50% | -0.46% | -8.94% | -27.36% | 4.67% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -41.54 | -22.04 | -10.87 | -6.91 | -151.05 |
| Price-to-Sales (P/S) Ratio | 2.86 | 3.29 | 5.27 | 4.43 | 2.03 |
| Price-to-Book (P/B) Ratio | 2.92 | 2.85 | 3.83 | 2.13 | 3.33 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -201.65 | -217.45 | -11.19 | -3.65 | 21.39 |
| Price-to-Operating Cash Flow Ratio | 92.17 | 119.03 | -12.12 | -4.15 | 15.42 |
| Price-to-Earnings Growth (PEG) Ratio | 0.88 | 0.35 | 0.64 | -0.01 | 1.79 |
| Enterprise Value Multiple | 222.51 | 42.40 | -6.50 | -3.32 | 5.07 |
| Enterprise Value | 4.15B | 4.19B | 6.79B | 5.44B | 6.87B |
| EV to EBITDA | 222.51 | 42.40 | -6.50 | -3.32 | 5.07 |
| EV to Sales | 2.62 | 3.06 | 5.87 | 5.15 | 1.75 |
| EV to Free Cash Flow | -185.10 | -202.07 | -12.45 | -4.26 | 18.42 |
| EV to Operating Cash Flow | 84.61 | 110.61 | -13.49 | -4.83 | 13.27 |
| Tangible Book Value Per Share | 33.14 | 35.44 | 35.10 | 45.70 | 45.35 |
| Shareholders’ Equity Per Share | 11.11 | 11.36 | 11.42 | 15.77 | 17.23 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.35 | -0.97 | -0.15 | -0.04 | 0.05 |
| Revenue Per Share | 11.34 | 9.85 | 8.31 | 7.59 | 28.23 |
| Net Income Per Share | -0.78 | -1.47 | -4.03 | -4.86 | -0.38 |
| Tax Burden | 0.50 | 1.82 | 0.44 | 0.42 | -0.04 |
| Interest Burden | 1.39 | 1.48 | 1.05 | 0.88 | 1.07 |
| Research & Development to Revenue | 0.28 | 0.29 | 1.15 | 1.25 | 0.35 |
| SG&A to Revenue | 0.32 | 0.42 | 0.43 | 0.38 | 0.10 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.02 | 0.08 | 0.02 |
| Income Quality | -0.45 | -0.34 | 0.90 | 1.67 | -9.83 |
Currency in TWD
